Cytogenetic abnormalities commonly associated with multiple myeloma (MM) are detected by fluorescence in situ hybridization (FISH). Probes for CKS1B-CDKN2C (1p32.3/1q21.3), 5q (5q-/-5/+5), 13q (13q-/-13), TP53 (17p13.1), IGH/FGFR3 t(4;14), IGH/CCND1 t(11;14), IGH/MAF t(14;16), IGH/MAFB t(14;20) are included in the Myeloma FISH Profile.
disease state indication(s)
Multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS)
The Myeloma FISH Profile detects cytogenetic abnormalities that can help genetically subclassify and risk stratify patients with multiple myeloma (MM). Standard-risk cytogenetic abnormalities include hyperdiploidy and t(11;14), while high-risk cytogenetic abnormalities include del(17/17p), t(4;14), t(14;16), t(14;20), and gain(1q) .
1. Sonneveld P, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the Internal Myeloma Working Group. Blood 2016;127:2955-2962.
Fluorescence in situ hybridization (FISH)
specimen type and requirements
Peripheral blood: 5-6 mL in sodium heparin (green-top) tube.
Bone marrow: 2-3 mL in sodium heparin (green-top) tube.
Bodily fluids: Bodily fluids for diagnostic testing of hematological cancers (subject to specimen viability). Preferred transport in equal parts RPMI.
Lymphoid tissue: Transport in RPMI.
FFPE tissue: no decalcification (except for centromere as well as locus specific FISH probes).
Note: Use refrigerated cold pack for transport. Make sure cold pack is not in direct contact with specimen.
DO NOT FREEZE.
Probe Prioritization: If samples are insufficient to complete the whole FISH panel, Genoptix will prioritize testing in the following order: IGH/FGFR3, TP53, CKS1B-CDKN2C, IGH/MAF, IGH/MAFB, IGH/CCND1, 5q, and 13q, unless directed otherwise by the client. The remaining probes will be completed on the unenriched cells if available.
Tech-only (TC): 3 days
Global (TC & PC): 5 days
medicare moldx cpt code
Laboratory developed test (LDT)
Global (TC & PC) or Tech-only (TC)